Tharu Tharakan

Tharu Tharakan

Auto-generated profile, based on publicly available information

Tharu Tharakan

Department of Urology, Imperial Healthcare NHS Trust, Charing Cross Hospital, London, UK

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2021 in Faculty Reviews
Verified
Journal Article
Closed access
PDF file
TTTharu Tharakan
Tharu Tharakan
RLRong Luo
Rong Luo
CJChanna N Jayasena
Channa N Jayasena
SMSuks Minhas
Suks Minhas
Non-obstructive azoospermia: current and future perspectives

1 January 2022 in European Urology Focus
Verified
Journal Article
Closed access
TTTharu Tharakan
Tharu Tharakan
CBCarlo Bettocchi
Carlo Bettocchi
JCJoana Carvalho
Joana Carvalho
GCGiovanni Corona
Giovanni Corona
TJThomas Hugh Jones
Thomas Hugh Jones
SMSuks Minhas
Suks Minhas

8 May 2022 in Human Reproduction Update
Verified
Journal Article
Open access
PDF file
TTTharu Tharakan
Tharu Tharakan
GCGiovanni Corona
Giovanni Corona
DFDaniel Foran
Daniel Foran
ASAndrea Salonia
Andrea Salonia
NSNikolaos Sofikitis
Nikolaos Sofikitis
SMSuks Minhas
Suks Minhas
The beneficial effects of hormonal therapy in stimulating spermatogenesis in patients with non-obstructive azoospermia (NOA) and either normal gonadotrophins or hypergonadotropic hypogonadism prior to surgical sperm retrieval (SSR) is controversial. Although the European Association of Urology guidelines state that hormone stimulation is not recommended in routine clinical practice, a significant number of patients undergo empiric therapy prior to SSR. The success rate for SSR from microdissection testicular sperm extraction is only 40–60%, thus hormonal therapy could prove to be an effective adjunctive therapy to increase SSR rates. The primary aim of this systematic review and meta-analysis was to compare the SSR rates in men with NOA (excluding those with hypogonadotropic hypogonadism) receiving hormone therapy compared to placebo or no treatment. The secondary objective was to compare the effects of hormonal therapy in normogonadotropic and hypergonadotropic NOA men. A literature search was performed using the Medline, Embase, Web of Science and Clinicaltrials.gov databases from 01 January 1946 to 17 September 2020. We included all studies where hormone status was confirmed. We excluded non-English language and animal studies. Heterogeneity was calculated using I2 statistics and risk of bias was assessed using Cochrane tools. We performed a meta-analysis on all the eligible controlled trials to determine whether hormone stimulation (irrespective of class) improved SSR rates and also whether this was affected by baseline hormone status (hypergonadotropic versus normogonadotropic NOA men). Sensitivity analyses were performed when indicated. A total of 3846 studies were screened and 22 studies were included with 1706 participants. A higher SSR rate in subjects pre-treated with hormonal therapy was observed (odds ratio (OR) 1.96, 95% CI: 1.08–3.56, P = 0.03) and this trend persisted when excluding a study containing only men with Klinefelter syndrome (OR 1.90, 95% CI: 1.03–3.51, P = 0.04). However, the subgroup analysis of baseline hormone status demonstrated a significant improvement only in normogonadotropic men (OR 2.13, 95% CI: 1.10–4.14, P = 0.02) and not in hypergonadotropic patients (OR 1.73, 95% CI: 0.44–6.77, P = 0.43). The literature was at moderate or severe risk of bias. This meta-analysis demonstrates that hormone therapy is not associated with improved SSR rates in hypergonadotropic hypogonadism. While hormone therapy improved SSR rates in eugonadal men with NOA, the quality of evidence was low with a moderate to high risk of bias. Therefore, hormone therapy should not be routinely used in men with NOA prior to SSR and large scale, prospective randomized controlled trials are needed to validate the meta-analysis findings.

18 November 2021 in Nature Reviews Urology
Verified
Journal Article
Closed access
PDF file
TTTharu Tharakan
Tharu Tharakan
CKChristopher C. Khoo
Christopher C. Khoo
AGAleksander Giwercman
Aleksander Giwercman
CJChanna N Jayasena
Channa N Jayasena
NSNikolaos Sofikitis
Nikolaos Sofikitis
SMSuks Minhas
Suks Minhas

1 July 2020 in European Urology Focus
Verified
Journal Article
Closed access
TTTharu Tharakan
Tharu Tharakan
CBCarlo Bettocchi
Carlo Bettocchi
Joana CarvalhoJoana Carvalho
Joana Carvalho
GCGiovanni Corona
Giovanni Corona
UJUlla Nordström Nordström Joensen
Ulla Nordström Nordström Joensen
SMSuks Minhas
Suks Minhas

25 March 2019 in F1000Research
Verified
Journal Article
Open access
PDF file
TTTharu Tharakan
Tharu Tharakan
SMSaiful Miah
Saiful Miah
CJChanna N Jayasena
Channa N Jayasena
SMSuks Minhas
Suks Minhas
Late-onset hypogonadism (LOH) is the term used to describe the decline in serum testosterone levels associated with increasing age in men above 40 years. A number of symptoms are attributed to LOH, but the most common association is that of sexual dysfunction. LOH has recently come under greater scrutiny with the widespread use of testosterone therapy, and concerns regarding the efficacy and safety of testosterone replacement therapy have been raised. In particular, the cardiovascular safety and the beneficial effects of testosterone replacement therapy on general health have been questioned. This review will give an overview of the current evidence for the relationship of LOH and male sexual dysfunction.